Persistently positive antiphospholipid antibodies in association with thromboses and/or pregnancy morbidity is the hallmark of the antiphospholipid syndrome. The management of antiphospholipid antibody-positive patients has been focused on utilizing anti-thrombotic medications such as heparin or warfarin. Given that our understanding of the molecular mechanisms of antiphospholipid antibody-mediated thrombosis has been growing, it is highly likely that the current ‘anti-thrombotic’ approach to these patients will be replaced by an ‘immunomodulatory’ approach in the near future. This review article will address the experimental and/or clinical evidence behind some of these potential ‘immunomodulatory’ approaches (tissue factor inhibition, P38 mitogen-activated protein kinase inhibition, nuclear factor-κB inhibition, platelet glycoprotein receptor inhibition, hydroxychloroquine, statins, inhibition of β2GPI and/or anti-β2GPI binding to target cells, complement inhibition, and B cell inhibition) in antiphospholipid syndrome.
Miyakis S., Lockshin MD, Atsumi T., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost2006; 4: 295-306.
2.
Erkan D., Harrison M., Levy R., et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum2007; 56: 2382-2391.
3.
Fischetti F. , Durigutto P., Pellis V., et al. Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor . Blood2005; 106: 2340-2346.
4.
Meroni PL, Raschi E., Carrera M., et al. Endothelia activation of aPL; a potential pathogenic mechanism for the clinical manifestations of the syndrome. J Autoimmun2000; 15: 237-240.
5.
Amengual O., Atsumi T., Khamashta M., et al. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb Haemost1998; 79: 276-281.
6.
Cuadrado MJ, Buendia P., Velasco F., et al. Vascular endothelial growth factor expression in monocytes from patients with primary antiphospholipid syndrome. J Thromb Haemost2006; 4: 2461-2469.
7.
Zhou H., Wolberg AS, Roubey ASCharacterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep. Blood2004; 15: 2353-2358.
8.
Forastiero RR , Martinuzzo ME, de Larranaga GFCirculating levels of tissue factor and proinflammatory cytokines in patients with primary antiphospholipid syndrome or leprosy related antiphospholipid antibodies. Lupus2005; 14: 129-136.
9.
Forastiero RR , Martinuzzo ME, Broze GJHigh titers of autoantibodies to tissue factor pathway inhibitor are associated with the antiphospholipid syndrome. J Thromb Haemost2003; 1: 718-724.
10.
Williams FMK , Parmar K., Hughes GRV, Hunt BJSystemic endothelial cell markers in primary antiphospholipid syndrome. J Thromb Haemost2000; 84: 742-746.
11.
de Prost D.Pentoxifylline: a potential treatment for thrombosis associated with abnormal tissue factor expression by monocytes and endothelial cells. J Cardiovasc Pharmacol1995; 25(Suppl 2): S114-S118.
12.
Burcoglu-O’Ral A., Erkan D., Asherson RATreatment of catastrophic antiphospholipid syndrome with defibrotide, a proposed vascular endothelial cell modulator . J Rheumatol2002; 29: 2006-2011.
13.
Napoleone E. , Di Santo A., Camera M., et al. Angiotensin-converting enzyme inhibitors downregulate tissue factor synthesis in monocytes. Circ Res2000 ; 86: 139-143.
14.
Espinola RG , Liu X., Colden-Stanfield M., et al. E-Selectin mediates pathogenic effects of antiphospholipid antibodies . J Thromb Haemost2003; 1: 843-848.
15.
Dunoyer-Geindre S., de Moerloose P., Galve-de Rochemonteiz B., et al. NF-κB is an essential intermediate in the activation of endothelial cells by anti-β2glycoprotein I antibodies. Thromb Haemost2002; 88: 851-857.
16.
Bohgaki M., Atsumi T., Yamashita Y., et al. The p38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti-b2Glycoprotein I antibodies. Int Immunol2004; 16: 1633-1641.
17.
Vega-Ostertag ME, Harris EN, Pierangeli SSIntracellular events in platelet activation induced by antiphospholipid antibodies in the presence of low doses of thrombin . Arthritis Rheum2004; 50: 2911-2919.
18.
Vega-Ostertag ME, Carper K., Swerlick R., et al. Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies. Arthritis Rheum2005; 52: 1545-1554.
19.
Simoncini S. , Sapet C., Camoin-Jau L., et al. Role of reactive oxygen species and p38 MAPK in the induction of the pro-adhesive endothelial state mediated by IgG from patients with anti-phospholipid syndrome. Int Immunol2004; 17: 489-500.
20.
Vega-Ostertag ME, Ferrara DE, Romay-Penabad Z., et al. Role of p38 mitogen-activated protein kinase in antiphospholipid antibody-mediated thrombosis and endothelial cell activation. J Thromb Haemost2007; 5: 1828-1834.
21.
Montiel-Manzano G., Romay-Penabad Z., Papalardo de Martinez E., et al. In vivo effects of an inhibitor of nuclear factor-kappa B on thrombogenic properties of antiphospholipid antibodies. Ann NY Acad Sci2007; 1108: 540-553.
Pierangeli SS, Vega-Ostertag M., Gonzalez EBNew targeted therapies for treatment of thrombosis in antiphospholipid syndrome. Expert Rev Mol Med2007; 9: 1-15.
24.
Aikawa M., Rabkin E., Sugiyama S., et al. An HMG-CoA inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro . Circulation2001; 103: 276-283.
25.
Jiménez S., Tassies D., Espinosa G., et al. Double heterozygosity polymorphisms for platelet glycoproteins Ia/IIa and IIb/IIIa increases arterial thrombosis and arteriosclerosis in patients with the antiphospholipid syndrome or with systemic lupus erythematosus. Ann Rheum Dis2008; 67: 835-840.
26.
Straub A., Wendel HP, Azevedo R., Ziemer G.The GP IIb/IIIa inhibitor abciximab (ReoPro) decreases activation and interaction of platelets and leukocytes during in vitro cardiopulmonary bypass simulation . Eur J Cardiothorac Surg2005; 27: 617-621.
27.
Jancinova V. , Nosal R., Petrikova M.On the inhibitory effect of chloroquine on blood platelet aggregation. Thromb Res1994 ; 74: 495-504.
28.
Lombard-Platlet S., Bertolino P., Deng H., Gerlier D., Rabourdin-Combe C.Inhibition by chloroquine of the class II major histocompatibility complex-restricted presentation of endogenous antigens varies according to the cellular origin of the antigen-presenting cells, the nature of the T-cell epitope, and the responding T cell. Immunology1993; 80: 566-573.
29.
Goldman FD, Gilman AL, Hollenback C., et al. Hydroxychloroquine inhibits calcium signals in T cells: a new mechanism to explain its immunomodulatory properties. Blood2000; 95: 3460-3466.
30.
Pierangeli SS, Vega-Ostertag M., Harris ENIntracellular signaling triggered by antiphospholipid antibodies in platelets and endothelial cells: a pathway to targeted therapies . Thromb Res2004; 114: 467-476.
31.
Rand JH, Wu XX, Quinn AS, et al. Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers. Blood2008; 112: 1687-1695.
32.
Rand JH, Wu XX, Quinn AS, et al. Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug. Blood2009; ([Epub ahead of print]).
33.
Johnson R., Charnley J.Hydroxychloroquine in prophylaxis of pulmonary embolism following hip arthroplasty . Clin Orthop Relat Res1979; 144: 174-177.
34.
Wallace DJDoes hydroxychloroquine protect against clot formation in systemic lupus erythematosus?Arthritis Rheum1997 ; 30: 1435-1436.
35.
Petri M.Lupus in Baltimore: evidence-based ‘clinical pearls’ from the Hopkins Lupus Cohort. Lupus2005; 14: 970-973.
36.
Kaiser R., Cleveland CM, Criswell LARisk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort. Ann Rheum Dis2009; 68: 238-241.
37.
Tektonidou MG, Laskari K., Panagiotakos DB, Moutsopoulos HMRisk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum2009; 61: 29-36.
38.
Ho KT, Ahn CW, Alarcon GS, et al. Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events. Rheumatology (Oxford) 2005; 44: 1303-1307.
39.
Ruiz-Irastorza G., Egurbide MV, Pijoan JL, et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus2006; 15: 577-583.
40.
Erkan D., Yazici Y., Peterson MG, et al. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology (Oxford) 2002; 41: 924-929.
41.
McCarty GA, Cason TEUse of hydroxychloroquine in antiphospholipid antibody syndrome at three academic rheumatology units over two years: improvement in antibody titer and symptom management. 7th International Congress on SLE and related conditions abstract book 2004; M17A (abstract).
42.
Erkan D., Derksen WJ, Kaplan V., et al. Real world experience with antiphospholipid antibodies (aPL) How stable and significant are aPL?. Ann Rheum Dis2005; 64: 1321-1325.
43.
Colli S., Eligini S., Lalli M., et al. Statins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis. Arterioscler Thromb Vasc Biol1997; 17: 265-272.
44.
Halcox JPJ , Deanfield JEBeyond the laboratory.Clinical implications for statin pleitropy. Circulation2004; 109(Suppl II): 42-48.
45.
Baetta R., Camera M., Comparato C., et al. Fluvastatin reduces tissue factor expression and macrophage accumulation in carotid lesions of cholesterol-fed rabbits in absence of lipid lowering. Arterioscler Thromb Vasc Biol2002 ; 22: 692-698.
46.
Cortellaro M., Cofrancesco E., Arbustini E., et al. Atorvastatin and thrombogenicity of the carotid atherosclerotic plaque: the ATROCAP study . Thromb Haemost2002; 88: 41-47.
47.
Ridker PM, Danielson E., Fonseca FA, et al. JUPITER Trial Study Group. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet2009; 373: 1175-1182.
48.
Glynn RJ, Danielson E., Fonseca FA, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med2009; 360: 1851-1861.
49.
Meroni PL, Raschi E., Testoni C., et al. Statins prevent endothelial cell activation induced by antiphospholipid (anti-β2glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype. Arthritis Rheum2001; 44: 2870-2878.
50.
Ferrara DE, Liu X., Espinola RG, et al. Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model. Arthritis Rheum2003; 48: 3272-3279.
51.
Ferrara DE, Swerlick R., Casper K., et al. Fluvastatin inhibits upregulation of tissue factor expression by antiphospholipid antibodies on endothelial cells. J Thromb Haemost2004; 2: 1558-1563.
52.
Martínez-Martínez LA, Amigo MC, Orozco A., et al. Effect of rosuvastatin on VCAM-1 expression by HUVEC exposed to APS serum in an in vitro model. Clin Exp Rheumatol2007; 25: 18-19.
Kumar SS, Papalardo E., Jajoria P., et al. Effects of fluvastatin on prothrombotic/proinflammatory markers in patients with Antiphospholipid Syndrome. Arthritis Rheum2008; 58: S172 (abstract).
55.
Cuadrado MJ , Lopez-Pedrera C., Aguirre A., et al. Changes operated in protein pattern of monocytes from patients with antiphospholipid syndrome treated with statins . Arthritis Rheum2007; 56: S782 (abstract).
56.
Bouma B., De Groot PhG, Van Der Elsen JMH, et al. Adhesion mechanism of human B2glycoprotein-I to phospholipids based on its crystal structure. EMBO J1999 ; 18: 5166-5174.
57.
Ostertag MV , Liu X., Henderson V., Pierangeli SSA peptide that mimics the Vth region of β2-glycoprotein I reverses antiphospholipid-mediated thrombosis in mice. Lupus2006; 15: 358-365.
58.
Ma K., Simantov R., Zhang J., et al. High affinity binding of β2glycoprotein I to human endothelial cells is mediated by Annexin II. J Biol Chem2000; 275: 15541-15548.
59.
Zhang J., McCrae KRAnnexin A2 mediates endothelial cell activation by antiphospholipid/β2glycoprotein I antibodies. Blood2005; 105: 1964-1969.
60.
Romay-Penabad Z., Montiel-Manzano MG, Shilagard T., et al. Annexin A2 is involved in antiphospholipid antibody-mediated pathogenic effects in vitro and in vivo. Blood2009; 114: 3074-3083.
61.
Raschi E., Testoni C., Bosisio D., et al. Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. Blood2003; 101: 3495-3500.
62.
Zhang J., Lieske K., McCrae B., McCrae K.Activation of endothelial cells by β2glycoprotein I (β2GPI) antibodies is mediated by annexin II cross linking and may involve TLR4. Blood2004; 104: 83 (abstract).
63.
Sorice M., Longo A., Capozzi A., et al. Anti-β2glycoprotein I antibodies induce monocyte release of tumor necrosis factor alpha and tissue factor by signal transduction involving lipid rafts. Arthritis Rheum2007; 56: 2687-2697.
64.
Pierangeli SS, Vega-Ostertag ME, Raschi E., et al. Toll like receptor-4 is involved in antiphospholipid-mediated thrombosis: in vivo studies. Ann Rheum Dis2007; 66: 1327-1333.
65.
Andersen OM , Benhayon D., Curran T., Willnow TEDifferential binding of ligands to the apolipoprotein E receptor 2’. Biochemistry2003; 42: 9355-9364.
66.
Pinson KI, Brennan J., Monkley S., et al. An LDL-receptor-related protein mediates Wnt signaling in mice . Nature2000; 407: 535-538.
67.
Van Lummel M., Pennings MTT, Derksen RHWM, et al. The binding site of β2glycoprotein I for apoER2’ on platelets is located in Domain V. J Biol Chem2005; 280: 36279-36736.
68.
Lutters BCH , Derksen Rhwm, Tekelenburg WL, et al. Dimers of β2glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2’. J Biol Chem2003; 278: 33831-33838.
69.
DeLaat B., Derksen RH, Urbanus RT, deGroot PGIgG antibodies that recognize epitope Gly40-Arg 43 in domain I of β2glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood2005; 105: 1540-1545.
70.
Ioannou Y., Giles I., Lambrianides A., et al. A novel expression system of domain I of human b2glycoprotein I in Escherichia coli. BMC Biotechnol2006 ; 6: 8.
71.
Ioannou Y., Pericleous C., Giles I., et al. Binding of Antiphospholipid antibodies to discontinuous epitopes on domain I of human b2glycoprotein I. Mutation studies including residues R39 to R43. Arthritis Rheum2007; 56: 280-290.
72.
Ioannou Y., Romay-Penabad Z., Periclerous C., et al. In vivo inhibition of antibody-induced pathogenicity utilizing the antigenic target peptide domain I of β2glycoprotein I: proof of concept . J Thromb Haemost2009; 7: 833-842.
73.
Holers VM, Girardi G., Mo L., et al. C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med2002; 195: 211-220.
74.
Salmon JE, Girardi G., Holers VMComplement activation as a mediator of antiphospholipid antibody induced pregnancy loss and thrombosis. Ann Rheum Dis2002; 61: 46-50.
75.
Pierangeli SS, Girardi G., Vega-Ostertag ME, et al. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum2005; 52: 2120-2124.
76.
Romay-Penabad Z., Liu X., Montiel-Manzano G., et al. C5a receptor-deficient mice are protected from thrombophilia and endothelial cell activation induced by some antiphospholipid antibodies. NY Acad Sci2007; 1108: 554-566.
77.
Ricklin D., Lambris J.Complement-targeted therapies. Nat Biotechnol2007; 25: 1265-1275.
78.
Carrera-Marín AL, Romay-Penabad Z., Qu HC, et al. A C5a receptor antagonist ameliorates in vivo effects of antiphospholipid antibodies. Arthritis Rheum2009; 60: s767 (abstract).
79.
Girardi G., Redecha P., Salmon JEHeparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med2004; 10: 1222-1226.
80.
Munakata Y. , Saito T., Matsuda K., et al. Detection of complement-fixing antiphospholipid antibodies in association with thrombosis . Thromb Haemost2000; 83: 728-731.
81.
Oku K., Atsumi T., Bohgaki M., et al. Complement activation in patients with primary antiphospholipid syndrome. Ann Rheum Dis2008; 68: 1030-1035.
82.
Davis WD, Brey RLAntiphospholipid antibodies and complement activation in patients with cerebral ischemia. Clin Exp Immunol1992 ; 10: 455-460.
83.
Youinou P., Reneaudineau Y.The antiphospholipid syndrome as a model for B-cell-induced autoimmune diseases . Thromb Res2004; 114: 363-369.
84.
Kahn P., Ramanujman M., Bethunaickan R., et al. Prevention of murine antiphospholipid syndrome by BAFF blockade . Arthritis Rheum2008; 58: 2824-2283.
85.
Akkerman A. , Huang W., Wang X., et al. CTLA4Ig prevents initiation but not evolution of anti-phospholipid syndrome in NZW/BXSB mice . Autoimmunity2004; 37: 445-451.
86.
Erre GL, Pardini S., Faedda R., et al. Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome: a case report and a review of literature. Lupus2008; 17: 50-55.
87.
Tenedios F. , Erkan D., Lockshin MDRituximab in the primary antiphospholipid antibody syndrome. Arthritis Rheum2005; 52: 4078 (abstract).
88.
Erdozain JG , Ruiz-Irastorza G., Egurbide MV, et al. Sustained response to rituximab of autoimmune hemolytic anemia associated with antiphospholipid syndrome. Haematologica2004; 89: ECR34 (abstract).
89.
Rubenstein E., Arkfeld DG, Metyas S., et al. Rituximab treatment for resistant antiphospholipid syndrome. J Rheumatol2006 ; 33: 355-357.
90.
Biasucci LM , Vitelli A., Liuzzo G., et al. Elevated levels of interleukin-6 in unstable angina. Circulation1996; 94: 874-877.
91.
Fisman EZ, Benderly M., Esper RJ, et al. Interleukin-6 and the risk of future cardiovascular events in patients with angina pectoris and/or healed myocardial infarction. Am J Cardiol2006; 98: 14-18.
92.
Del Papa N. , Guidali L., Sala A., et al. Endothelial cells as target for antiphospholipid antibodies. Human polyclonal and monoclonal anti-beta 2-glycoprotein I antibodies react in vitro with endothelial cells through adherent beta 2-glycoprotein I and induce endothelial activation. Arthritis Rheum1997; 40: 551-561.
93.
Bernales I. , Fullaondo A., Marin-Vidalled MJ, et al. Innate immune response gene expression profiles characterize primary antiphospholipid syndrome . Genes Immun2008; 9: 38-46.
94.
Salobir B., Sabovic M.Interleukin-6 and antiphospholipid antibodies in women with contraceptive-related thromboembolic disease. Obstet Gynecol2004 ; 104: 564-570.
